Clinical consequences of MRI activity in treated multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 9, 2011, Pages 1113-1121

  Cadavid, Diego ^a   Kim, Soyeon ^a   Peng, Bo ^a   Skurnick, Joan ^a   Younes, Maha ^a   Hill, James ^a   Wolansky, Leo J ^a   Cook, Stuart D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Disability; glatiramer acetate; interferon beta 1b; MRI; multiple sclerosis

Indexed keywords

GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; COGNITION; DISEASE COURSE; DISEASE EXACERBATION; DRUG MONITORING; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; WALKING DIFFICULTY;

EID: 84860389894     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511405375     Document Type: Article

References (33)

1. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991 ; 41: 1219-1222
2. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991 ; 54: 683-688
3. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?. Ann Neurol. 2006 ; 59: 597-605
4. Rashid W, Davies GR, Chard DT, et al. Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Mult Scler. 2007 ; 13: 178-185 (Pubitemid 46592769)
5. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology. 2009 ; 72: 705-711
6. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004 ; 56: 548-555 (Pubitemid 39319345)
7. Durelli L, Barbero P, Bergui M, et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008 ; 79: 646-651 (Pubitemid 351829435)
8. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009 ; 15: 848-853
9. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009 ; 8: 545-559
10. Festa ED, Hankiewicz K, Kim S, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009 ; 15: 1271-1279
11. Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005 ; 15: 289-290 (Pubitemid 40863668)
12. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009 ; 72: 1976-1983
13. Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009 ; 80: 1337-1343
14. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 ; 73: 1485-1492
15. Koziol JA, Lucero A, Sipe JC, Romine JS, Beutler E. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. Can J Neurol Sci. 1999 ; 26: 283-289 (Pubitemid 29522813)
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
17. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122: 871-882 (Pubitemid 29219261)
18. Younes M, Hill J, Quinless J, et al. Internet-based cognitive testing in multiple sclerosis. Mult Scler. 2007 ; 13: 1011-1019 (Pubitemid 351541436)
19. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002 ; 16: 381-397 (Pubitemid 36390381)
20. Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler. 2006 ; 12: 594-598 (Pubitemid 46940633)
21. Ebers G, Heigehauser L, Daumer M, Lederer C, Noseworthy J. Disability as an outcome in MS clinical Trials. Neurology. 2008 ; 71: 624-631
22. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 ; 131: 808-817 (Pubitemid 351294716)
23. Sormani M, Bonzano L, Roccatagliata L, Cutter G, Mancardi G, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009 ; 65: 268-275
24. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology. 2010 ; 75: 302-309
25. Barkhof F. MRI in multiple sclerosis: correlation with Expanded Disability Status Scale (EDSS). Mult Scler. 1999 ; 5: 283-286 (Pubitemid 29405626)
26. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 1997 ; 49: 862-869 (Pubitemid 27428037)
27. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 ; 32: 758-766
28. Miki Y, Grossman RI, Udupa JK, et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images-lack of correlation between changes in T2 lesion volume and clinical findings. Radiology. 1999 ; 213: 395-399 (Pubitemid 29510584)
29. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995 ; 45: 255-260
30. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler. 2004 ; 10: 41-46 (Pubitemid 38100525)
31. Cadavid D, Tang Y and O'Neill G. Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol 2010; 51: 321-9.
32. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999 ; 5: 244-250 (Pubitemid 29405620)
33. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology. 2001 ; 56: 1324-1330 (Pubitemid 32455292)